Atossa Genetics (NASDAQ:ATOS) was downgraded by Sidoti from a “buy” rating to a “neutral” rating in a research note issued on Monday, TheFlyOnTheWall.com reports.
Shares of Atossa Genetics (NASDAQ:ATOS) traded down 8.77% on Monday, hitting $2.60. 699,858 shares of the company’s stock traded hands. Atossa Genetics has a one year low of $2.54 and a one year high of $12.40. The stock’s 50-day moving average is $4.95 and its 200-day moving average is $5.71. The company’s market cap is $40.5 million.
Atossa Genetics (NASDAQ:ATOS) last released its earnings data on Wednesday, August 14th. The company reported ($0.17) EPS for the quarter. The company had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.28 million. Analysts expect that Atossa Genetics will post $-0.55 EPS for the current fiscal year.
Atossa Genetics Inc is a development-stage healthcare company focused on the prevention of breast cancer through the commercialization of diagnostic tests that can detect precursors to breast cancer, and through the research, development, and ultimate commercialization of treatments for pre-cancerous lesions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.